239 related articles for article (PubMed ID: 35655708)
1.
Tomita Y; Goto Y; Sakata S; Imamura K; Minemura A; Oka K; Hayashi A; Jodai T; Akaike K; Anai M; Hamada S; Iyama S; Saruwatari K; Saeki S; Takahashi M; Ikeda T; Sakagami T
Oncoimmunology; 2022; 11(1):2081010. PubMed ID: 35655708
[TBL] [Abstract][Full Text] [Related]
2. Association of
Tomita Y; Sakata S; Imamura K; Iyama S; Jodai T; Saruwatari K; Hamada S; Akaike K; Anai M; Fukusima K; Takaki A; Tsukamoto H; Goto Y; Motozono C; Sugata K; Satou Y; Ueno T; Ikeda T; Sakagami T
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201474
[TBL] [Abstract][Full Text] [Related]
3. Supplemental Clostridium butyricum MIYAIRI 588 Affects Intestinal Bacterial Composition of Finishing Pigs.
Hirata M; Matsuoka M; Hashimoto T; Oura T; Ohnuki Y; Yoshida C; Minemura A; Miura D; Oka K; Takahashi M; Morimatsu F
Microbes Environ; 2022; 37(3):. PubMed ID: 36155363
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
5. Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus.
Zhang Y; Lu M; Zhang Y; Yuan X; Zhou M; Xu X; Zhang T; Song J
Ann N Y Acad Sci; 2023 Nov; 1529(1):84-100. PubMed ID: 37658670
[TBL] [Abstract][Full Text] [Related]
6. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
7. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
[TBL] [Abstract][Full Text] [Related]
8. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
9. Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer.
Tian Y; Liu Z; Pan H; Zhu H; Zou N; Jiang L; Li Z; Huang J; Hu Y; Luo Q
Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38530978
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous transhepatic cholangial drainage or antibiotic therapy worsens response to immunotherapy in advanced cholangiocarcinoma.
Huang Q; Wang F; Zhang X; Liu J; Dou X; Feng R; Zhu K; Jiang S; Zhang Y; Yue J
BMC Cancer; 2023 Jul; 23(1):657. PubMed ID: 37442960
[TBL] [Abstract][Full Text] [Related]
11.
Cao W; Zheng C; Xu X; Jin R; Huang F; Shi M; He Z; Luo Y; Liu L; Liu Z; Wei J; Deng X; Chen T
Front Immunol; 2022; 13():1076245. PubMed ID: 36466862
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors affect the gut microbiome.
Imhann F; Bonder MJ; Vich Vila A; Fu J; Mujagic Z; Vork L; Tigchelaar EF; Jankipersadsing SA; Cenit MC; Harmsen HJ; Dijkstra G; Franke L; Xavier RJ; Jonkers D; Wijmenga C; Weersma RK; Zhernakova A
Gut; 2016 May; 65(5):740-8. PubMed ID: 26657899
[TBL] [Abstract][Full Text] [Related]
13.
Ibáñez-Molero S; van Vliet A; Pozniak J; Hummelink K; Terry AM; Monkhorst K; Sanders J; Hofland I; Landeloos E; Van Herck Y; Bechter O; Kuilman T; Zhong W; Marine JC; Wessels L; Peeper DS
Oncoimmunology; 2022; 11(1):2139074. PubMed ID: 36465485
[TBL] [Abstract][Full Text] [Related]
14. Combining radiation therapy with immune checkpoint blockade for the treatment of small cell lung cancer.
Saxena A
Semin Cancer Biol; 2023 May; 90():45-56. PubMed ID: 36787870
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
16. A gut microbial signature for combination immune checkpoint blockade across cancer types.
Gunjur A; Shao Y; Rozday T; Klein O; Mu A; Haak BW; Markman B; Kee D; Carlino MS; Underhill C; Frentzas S; Michael M; Gao B; Palmer J; Cebon J; Behren A; Adams DJ; Lawley TD
Nat Med; 2024 Mar; 30(3):797-809. PubMed ID: 38429524
[TBL] [Abstract][Full Text] [Related]
17. The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors.
Jiang H; Ye Y; Wang M; Sun X; Sun T; Chen Y; Li P; Zhang M; Wang T
Biotechnol Genet Eng Rev; 2023 May; ():1-20. PubMed ID: 37191003
[TBL] [Abstract][Full Text] [Related]
18. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
[TBL] [Abstract][Full Text] [Related]
19. A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy.
Zhu X; Huang X; Hu M; Sun R; Li J; Wang H; Pan X; Ma Y; Ning L; Tong T; Zhou Y; Ding J; Zhao Y; Xuan B; Fang JY; Hong J; Hon Wong JW; Zhang Y; Chen H
Cell Host Microbe; 2024 Apr; 32(4):489-505.e5. PubMed ID: 38513657
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors.
Wang J; Zhu N; Su X; Yang R
Cancer Lett; 2024 Feb; 582():216582. PubMed ID: 38065401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
